apnimed.comHealthcareFounded: 2017Funding to Date: $208.02MM
Apnimed, founded in 2017, is a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, MA, the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.